Quick Takeaways
- KZR - Kezar Life Sciences, Inc. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q1 2026.
- Headline metric: Return On Equity -60%.
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2026.
Shareable Research Card
KZR - Kezar Life Sciences, Inc. has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.
Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest SEC snapshot (2026-03-23) highlights Return On Equity -59.9%, Return On Assets -50.6%, and Current Ratio 11.52x.
Use these links to compare KZR - Kezar Life Sciences, Inc. against other SEC filers on the same metric, then verify the company history from the paired facts page.
Latest value: 33%
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
38.8/100
Weak Confidence medium
-60%
Metric score 0.0/100
-51%
Metric score 0.0/100
Debt-to-equity and NetIncomeLoss YoY
Return On Equity, Return On Assets, and Current Ratio
Return On Equity
-60%
YoY: +9%
Industry median: -43% (n=675)
Return On Assets
-51%
YoY: +11%
Industry median: -47% (n=673)
Current Ratio
11.52x
YoY: +70%
Industry median: 3.39x (n=667)
Debt-to-equity
0.17x
YoY: -15%
Industry median: 0.26x (n=530)
NetIncomeLoss YoY
33%
YoY:
Industry median: -0.93% (n=641)
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Equity | -60% | +9% |
| Return On Assets | -51% | +11% |
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 11.52x | +70% |
| Debt-to-equity | 0.17x | -15% |
| Metric | Latest value | YoY change |
|---|---|---|
| NetIncomeLoss YoY | 33% |
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 7,371,527 | +0.9% |
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
Metrics are computed with a market-consensus convention designed for cross-portal comparability.